Search results for "HB"

showing 10 items of 1066 documents

Quantitative Ultrasound Bone Measurements in Pre-Pubertal Children with Type 1 Diabetes

2011

This case-control study aimed to assess bone status in children with type 1 diabetes mellitus (T1DM). Fifty-seven pre-pubertal patients (37 boys, aged 7.9 ± 2.5 years, T1DM duration 3.1 ± 1.6 years) and 171 age-matched healthy controls (111 boys) were studied. Quantitative ultrasound (QUS) was used to measure amplitude dependent speed of sound (Ad-SoS) at hand phalanges (expressed as standard deviation score [SDS]). Anthropometric and disease-related data (including mean HbA(1c) from whole T1DM duration [T], last year [Y], examination day [D]) were collected. Mean Ad-SoS SDS in patients -0.13 ± 1.32 (95% confidence interval [CI] -0.48, 0.22) was similar to that of controls. Subgroups discri…

MaleDiabetes durationmedicine.medical_specialtyHbA1cAcoustics and UltrasonicsBiophysicsSensitivity and SpecificityBone MeasurementsBone and BonesInternal medicineDiabetes mellitusmedicineHumansRadiology Nuclear Medicine and imagingChildBoneProspective cohort studyChildrenUltrasonographyType 1 diabetesRadiological and Ultrasound Technologybusiness.industryReproducibility of ResultsAnthropometrymedicine.diseaseConfidence intervalQuantitative ultrasoundDiabetes Mellitus Type 1Type 1 diabetesEndocrinologyChild PreschoolFemalebusinessQuantitative ultrasoundUltrasound in Medicine & Biology
researchProduct

Leisure‐time physical activity and participation in organized sports: Changes from 1985 to 2014 in Finland and Norway

2019

Participation in organized sports is a popular and important part of the lives of children and adolescents and is associated with improved psychological and social health, as well as an increased likelihood of meeting physical activity (PA) recommendations. Changes in modern society, including increased car ownership and use of technology and electronic media, have led to an additional focus on the importance of health‐enhancing PA among children and adolescents. The aim of this article was to study the secular changes in self‐reports of participation in organized sports clubs and leisure‐time vigorous physical activity (LVPA), and whether the relationship between participation in organized…

MaleGerontologyAdolescentLeisure timePhysical activityPhysical Therapy Sports Therapy and RehabilitationNorwegian030204 cardiovascular system & hematology03 medical and health sciencesLeisure Activities0302 clinical medicineSurveys and QuestionnairesHumansOrthopedics and Sports MedicineSocial determinants of healthUse of technologyChildFinlandHBSCyouthexerciseCar ownershipNorwaybusiness.industryYouth SportsOriginal Articles030229 sport sciencesElectronic medialanguage.human_languagePeer reviewtime changelanguageOriginal ArticleFemalememberSelf ReportPsychologybusinesshuman activities
researchProduct

Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection.

2003

Background & Aims: Occult hepatitis B virus (HBV) infection is characterized by persistence of HBV DNA into the tissue of hepatitis B surface antigen-negative individuals. The clinical relevance of this peculiar infection is still under debate. In particular, the impact of occult HBV infection in cases of hepatocellular carcinoma (HCC) is uncertain. We investigated the prevalence and molecular status of occult HBV in patients with HCC. Methods: We tested tumor tissues from 107 patients with HCC and the corresponding nontumor liver tissue from 72 of these patients for HBV DNA. We also examined liver specimens from 192 patients with chronic hepatitis. All cases were hepatitis B surface antige…

MaleHBV; HCC; occultHepatitis B virusCarcinoma HepatocellularOCCULT HEPATITIS B VIRUS INFECTION; HEPATOCELLULAR CARCINOMA; HBV DNA; TUNOR AND NONTUMOR LIVER TISSUES; HBV TRANSCRIPTS; HBV COVALENTLY CLOSED CIRCULAR DNA; INTEGRATED AND EPISOMAL HBV DNATranscription GeneticOCCULT HEPATITIS B VIRUS INFECTIONHBV TRANSCRIPTSGenome ViralBiologyVirus Replicationmedicine.disease_causeChronic liver diseaseHepatitis B ChronicmedicineCarcinomaHBVHumansHEPATOCELLULAR CARCINOMATUNOR AND NONTUMOR LIVER TISSUESHCCAgedHepatitis B virusHepatologyINTEGRATED AND EPISOMAL HBV DNALiver NeoplasmsGastroenterologyvirus diseasescccDNAMiddle AgedHepatitis Bmedicine.diseaseOccultVirologydigestive system diseaseshepatitis B surface antigenLiverViral replicationHBV DNAoccultHepatocellular carcinomaDNA ViralImmunologyFemaleHBV COVALENTLY CLOSED CIRCULAR DNAInfection OBI
researchProduct

A retrospective study of the role of delta agent infection in children with HBsAg-positive chronic hepatitis.

1985

The prevalence of intrahepatic delta antigen and/or anti-delta antibody was retrospectively investigated in 102 children with chronic HBsAg-positive hepatitis who were seen consecutively in three medical institutions between 1974 and 1982. Delta infection markers were found in 13 patients (12.7%) who exhibited high serum titers of anti-delta antibody; intrahepatic delta antigen was detected in ten. Eleven of the 13 children had severe progressive liver disease associated in all but one with absence of hepatitis B virus replication as evaluated by analysis of serum hepatitis B virus DNA. The factors which seem to increase the risk of delta infection in children who are hepatitis B virus carr…

MaleHBsAgCirrhosisAdolescentmedicine.disease_causeChronic liver diseaseHepatitisHepatitis B AntigensmedicineHumansChildRetrospective StudiesHepatitis B virusHepatitisHepatitis delta AntigensHepatitis B Surface AntigensHepatologybiologyChronic Activebusiness.industryInfantHepatitis delta Antigensmedicine.diseaseChild PreschoolImmunologyChronic Diseasebiology.proteinFemaleAntibodybusinessHepatology (Baltimore, Md.)
researchProduct

Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genot…

2019

Nucleos(t)ide analogues (NAs) and peginterferon have complementary effects in chronic hepatitis B, but it is unclear whether combination therapy improves responses in genotype D-infected patients. We conducted an open-label study of peginterferon alfa-2a 180 μg/week added to ongoing NA therapy in hepatitis B e antigen (HBeAg)-negative, genotype D-infected patients with HBV DNA <20 IU/mL. The primary endpoint was proportion of patients with ≥50% decline in serum HBsAg by the end of the 48-week add-on phase. Seventy patients received treatment, 11 were withdrawn at week 24 for no decrease in HBsAg, and 14 withdrew for other reasons. Response rate (per-protocol population) was 67.4% (29/43) at…

MaleHBsAgGastroenterologyPolyethylene Glycolschronic hepatitis B; HBeAg-negative; nucleos(t)ide analogues; peginterferon; treatment; Hepatology; Infectious Diseases; Virology0302 clinical medicineInterferonGenotypeHBVHepatitis B e Antigenspeginterferonchronic hepatitis b; hbeag-negative; nucleos(t)ide analogues; peginterferon; treatment; adult; antiviral agents; drug administration schedule; drug therapy combination; female; genotype; hepatitis b e antigens; hepatitis b virus; hepatitis b chronic; humans; interferon-alpha; male; middle aged; nucleosides; polyethylene glycols; recombinant proteins; treatment outcomeeducation.field_of_studytreatmentnucleos(t)ide analoguesvirus diseasesNucleosidesMiddle AgedRecombinant ProteinsTreatment OutcomeInfectious Diseasesnucleos(t)ide analogueHBeAg030220 oncology & carcinogenesisDrug Therapy CombinationFemale030211 gastroenterology & hepatologyPeginterferon alfa-2amedicine.drugAdultHepatitis B virusmedicine.medical_specialtyGenotypeCombination therapyPopulationHBeAg-negativeInfectious DiseaseHBeAg-negative; chronic hepatitis B; nucleos(t)ide analogues; peginterferon; treatmentchronic hepatitis B; HBeAg-negative; nucleos(t)ide analogues; peginterferon; treatmentAntiviral AgentsDrug Administration Schedule03 medical and health sciencesHepatitis B ChronicInternal medicineVirologymedicineHumanschronic hepatitis BeducationHepatologybusiness.industryInterferon-alphaConfidence intervalbusiness
researchProduct

Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants

2007

Objectives Because young infants are at highest risk of pertussis complications, this study assessed whether neonatal acellular pertussis (aP) vaccination could provide earlier immunity. Study design Neonates (n = 121) were randomly assigned (1:1) to receive either aP or hepatitis B vaccine (HBV) (controls) vaccine at birth, followed by vaccination with DTaP-HBV-IPV/Hib at 2, 4 and 6 months. Immune responses were measured. Reactogenicity was assessed for 7 days after each dose. Results The aP birth dose was followed by few adverse events. Reactogenicity of subsequent vaccine doses did not differ between groups. Seven serious adverse events were reported from each group; none were related to…

MaleHBsAgHepatitis B vaccineTime Factorsddc:616.07Bordetella pertussisDrug Administration ScheduleVaccines AcellularDouble-Blind MethodmedicineHumansWhooping coughPertussis VaccineVaccines Acellular/administration & dosageReactogenicityTetanusbusiness.industryDiphtheriaAge FactorsInfant NewbornInfantAntibodies Bacterial/bloodmedicine.diseasePertussis Vaccine/administration & dosageAntibodies BacterialVaccinationImmunoglobulin G/bloodImmunoglobulin GPediatrics Perinatology and Child HealthImmunologyFeasibility StudiesFemalePertactinbusinessBordetella pertussis/immunologyFollow-Up Studies
researchProduct

The effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hepatitis B vaccination in haemodialysis patients.

1996

Haemodialysis patients often fail to respond to hepatitis B vaccination. In this pilot study, 15 patients previously non-responsive to at least three 40 micrograms doses of hepatitis B vaccine were given 0.5, 5 or 10 micrograms kg-1 granulocyte-macrophage colony-stimulating factor (GM-CSF) subcutaneously 24 h prior to booster vaccination with a hepatitis B vaccine. Seven of the 15 patients developed antibody to hepatitis B surface antigen (HBsAb) (35-7240 IU L-1) upon initial vaccination with GM-CSF and two of four individuals responded with low HBsAb titres of 15 and 60 IU L-1 when revaccinated with hepatitis B surface antigen (HBsAg) and twice the dose of GM-CSF. The application of GM-CSF…

MaleHBsAgHepatitis B vaccinemedicine.medical_treatmentmedicine.disease_causeAdjuvants ImmunologicRenal DialysisVirologyMedicineHumansHepatitis B VaccinesHepatitis B AntibodiesAdverse effectAgedHepatitis B virusHepatitis B Surface AntigensHepatologybiologybusiness.industryGranulocyte-Macrophage Colony-Stimulating FactorImmunosuppressionHepatitis BMiddle Agedmedicine.diseaseHepatitis BVaccinationInfectious DiseasesImmunologybiology.proteinFemaleAntibodyHypotensionbusinessJournal of viral hepatitis
researchProduct

Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action.

1998

Abstract Background/Aims: To investigate the impact of hepatitis B (HBV) and C (HCV) infections on hepatocellular carcinoma (HCC) in Europe. Methods: Five hundred and three patients with HCC, from six liver centers, were included. All 503 sera and 80 liver samples were tested for HBV DNA and HCV RNA by polymerase chain reaction. GBV-C/HGV RNA was also tested in 57 sera. Results: HBsAg and anti-HCV were detected in 19% and 40.1% of the patients, respectively. Serum and liver HBV DNA were detected in 82% and 91% of the HBsAg positive subjects. HBV DNA was also detected in the serum and liver of 33% and 47% of HBsAg negative patients. In this group, serum HBV DNA was more prevalent in anti-HBs…

MaleHBsAgHepatitis B virusCarcinoma HepatocellularGenotypeHepatitis Viral HumanGbv c hgvHepacivirusPolymerase Chain Reactionlaw.inventionSerologylawGenotypeMedicineHumansPolymerase chain reactionAgedHepatitis B Surface AntigensHepatologybusiness.industryFlaviviridaeLiver NeoplasmsGastroenterologyvirus diseasesHepatitis BMiddle Agedmedicine.diseaseHepatitis BVirologyHepatitis Cdigestive system diseasesEuropeLiverHepatocellular carcinomaDNA ViralCoinfectionFemaleViral diseasebusinessJournal of hepatology
researchProduct

Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B virus profile reliable?

2009

Background/Aim: Patients with an occult hepatitis B virus (HBV) infection undergoing deep immunosuppression are potentially at risk of HBV reactivation. In order to assess whether a polymerase chain reaction (PCR) assay for HBV DNA in serum could be used to predict the reactivation of an occult HBV infection, we performed a retrospective study in a cohort of Sicilian patients with oncohaematological diseases. Methods: We studied by a highly sensitive ad hoc nested PCR for serum HBV DNA 75 HBsAg-negative oncohaematological patients requiring chemotherapy. Results: Thirty-three patients (44%) were HBV seronegative (anti-HBc and anti-HBs negative) and 42 patients (56%) were HBV seropositive (a…

MaleHBsAgHepatitis B virusHepatitis C virusAntineoplastic AgentsComorbiditymedicine.disease_causePolymerase Chain ReactionSerologyCohort StudiesBlood serumHepatitis B ChronicPredictive Value of TestsRecurrenceRisk FactorsmedicineHumansSeroconversionRetrospective StudiesHepatitis B virusHepatologybusiness.industryvirus diseasesHepatitis BMiddle Agedmedicine.diseasedigestive system diseasesItalyHematologic NeoplasmsImmunologyDNA ViralFemaleVirus ActivationbusinessNested polymerase chain reactionLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Detection of hepatitis B virus markers in sera of asymptomatic hepatitis B surface antigen carriers with special emphasis to pre-S-encoded proteins.

1987

Sera of asymptomatic hepatitis B surface antigen (HBsAg) carriers were analyzed for the presence of pre-S-encoded proteins. Four individuals with biopsy-proven chronic hepatitis uniformly expressed pre-S1- and pre-S2-encoded proteins. Individuals who had histologically normal or largely normal livers were heterogeneous with respect to expression of pre-S-encoded proteins. This heterogeneous expression of pre-S-encoded proteins occurred most likely due to difference in serum HBsAg concentration. Alternatively differences in pre-S gene expression need to be considered. Clinically the study indicates that expression of pre-S domains in serum is unrelated to viremia or chronic liver disease.

MaleHBsAgHepatitis B virusViremiamedicine.disease_causeChronic liver diseaseAsymptomaticGene expressionmedicineHumansProspective StudiesHepatitis B virusHepatitis B Surface Antigensbiologybusiness.industryGastroenterologyHepatitis Bmedicine.diseaseVirologyImmunologyCarrier StateDNA Viralbiology.proteinFemalemedicine.symptomAntibodybusinessDigestion
researchProduct